Birgitte Bentz Damholt

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 6

Top Topics

Placebo Controlled

Top Venues

Clinical pharmacokinetics

This page only lists publications with an associated author ORCID identifier.

Publications

Sarah Louise Dombernowsky, Birgitte Bentz Damholt, Michael Højby Rasmussen, Claus Sværke, Rasmus Juul Kildemoes
Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial. Clinical pharmacokinetics 63 (7) (2024)
Sarah Louise Dombernowsky, Birgitte Bentz Damholt, Michael Højby Rasmussen, Claus Sværke, Rasmus Juul Kildemoes
Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial. Clinical pharmacokinetics (2024)
Sarah Louise Dombernowsky, Birgitte Bentz Damholt, Michael Højby Rasmussen, Claus Sværke, Rasmus Juul Kildemoes
Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial. Clinical pharmacokinetics 63 (7) (2024)
Sarah Louise Dombernowsky, Birgitte Bentz Damholt, Michael Højby Rasmussen, Claus Sværke, Rasmus Juul Kildemoes
Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial. Clinical pharmacokinetics 63 (7) (2024)
Sarah Louise Dombernowsky, Birgitte Bentz Damholt, Michael Højby Rasmussen, Claus Sværke, Rasmus Juul Kildemoes
Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial. Clinical pharmacokinetics 63 (7) (2024)
Birgitte Bentz Damholt, Sarah Louise Dombernowsky, Mette Dahl Bendtsen, Charlotte Bisgaard, Michael Højby Rasmussen
Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials. Clinical pharmacokinetics 60 (8) (2021)